CeriBell, Inc. (NASDAQ:CBLL) Receives Average Rating of “Moderate Buy” from Analysts

Shares of CeriBell, Inc. (NASDAQ:CBLL) have received a consensus recommendation of “Moderate Buy” from the seven analysts that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $25.1667.

CBLL has been the topic of a number of research analyst reports. Raymond James Financial assumed coverage on CeriBell in a research report on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 price target on the stock. TD Cowen cut their price target on shares of CeriBell from $36.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Weiss Ratings restated a “sell (e+)” rating on shares of CeriBell in a report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. reduced their target price on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th.

Insider Activity at CeriBell

In related news, CTO Raymond Woo sold 11,112 shares of the stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $12.28, for a total transaction of $136,455.36. Following the completion of the transaction, the chief technology officer owned 167,704 shares in the company, valued at approximately $2,059,405.12. This represents a 6.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 23,090 shares of company stock valued at $285,941 over the last 90 days. Insiders own 20.10% of the company’s stock.

Institutional Trading of CeriBell

Several institutional investors and hedge funds have recently bought and sold shares of CBLL. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of CeriBell during the 3rd quarter worth approximately $33,000. KLP Kapitalforvaltning AS bought a new stake in CeriBell during the first quarter worth $36,000. Tower Research Capital LLC TRC grew its position in shares of CeriBell by 353.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after acquiring an additional 1,801 shares during the period. Ameritas Investment Partners Inc. increased its stake in shares of CeriBell by 97.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock worth $48,000 after purchasing an additional 1,256 shares during the last quarter. Finally, New York State Common Retirement Fund bought a new stake in CeriBell in the first quarter valued at approximately $67,000.

CeriBell Trading Up 11.9%

NASDAQ:CBLL traded up $1.62 during mid-day trading on Friday, hitting $15.26. The company had a trading volume of 1,079,265 shares, compared to its average volume of 316,485. The company has a debt-to-equity ratio of 0.12, a quick ratio of 12.25 and a current ratio of 12.65. CeriBell has a fifty-two week low of $10.01 and a fifty-two week high of $32.75. The firm has a market cap of $566.15 million and a P/E ratio of -10.11. The business’s fifty day moving average is $12.34 and its two-hundred day moving average is $14.37.

CeriBell (NASDAQ:CBLL) last issued its earnings results on Tuesday, November 4th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.06. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. The firm had revenue of $22.59 million during the quarter, compared to the consensus estimate of $21.78 million. CeriBell has set its FY 2025 guidance at EPS. As a group, research analysts expect that CeriBell will post -2.46 earnings per share for the current year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.